Early Access Program of Lazertinib in Republic of Korea

Summary

This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs Therapy.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications